Assembly Biosciences, Inc.

Assembly Biosciences Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative therapeutics targeting chronic hepatitis B virus (HBV) infection and other viral diseases. The company's primary goal is to create a functional cure for HBV, which is a global health concern due to its prevalence and potential to cause serious liver conditions, including cirrhosis and liver cancer. Assembly Biosciences Inc. leverages its expertise in microbiome science and drug development to advance its pipeline of product candidates. The firm also actively collaborates with leading research institutions and industry partners to enhance its capabilities in antiviral research. With headquarters in South San Francisco, California, Assembly Biosciences is uniquely positioned in the pharmaceutical industry to address unmet medical needs in infectious diseases through its cutting-edge research and development efforts. The company's activities significantly impact the healthcare sector by contributing to advancements in viral disease treatment, potentially improving patient outcomes and quality of life.